Regulation of Extrinsic Pathway Factor Xa Formation by Tissue Factor Pathway Inhibitor*

Tissue factor (TF) pathway inhibitor (TFPI) regulates factor X activation through the sequential inhibition of factor Xa and the VIIa·TF complex. Factor Xa formation was studied in a purified, reconstituted system, at plasma concentrations of factor X and TFPI, saturating concentrations of factor VIIa, and increasing concentrations of TF reconstituted into phosphatidylcholine:phosphatidylserine membranes (TF/PCPS) or PC membranes (TF/PC). The initial rate of factor Xa formation was equivalent in the presence or absence of 2.4 nm TFPI. However, reaction extent was small (<20%) relative to that observed in the absence of TFPI, implying the rapid inhibition of VIIa·TF during factor X activation. Initiation of factor Xa formation using increasing concentrations of TF/PCPS or TF/PC in the presence of TFPI yielded families of progress curves where both initial rate and reaction extent were linearly proportional to the concentration of VIIa·TF. These observations were consistent with a kinetic model in which the rate-limiting step represents the initial inhibition of newly formed factor Xa. Numerical analyses of progress curves yielded a rate constant for inhibition of VIIa·TF by Xa·TFPI (>108 m −1·s−1) that was substantially greater than the value (7.34 ± 0.8 × 106 m −1·s−1) directly measured. Thus, VIIa·TF is inhibited at near diffusion-limited rates by Xa·TFPI formed during catalysis which cannot be explained by studies of the isolated reaction. We propose that the predominant inhibitory pathway during factor X activation may involve the initial inhibition of factor Xa either bound to or in the near vicinity of VIIa·TF on the membrane surface. As a result, VIIa·TF inhibition is unexpectedly rapid, and the concentration of active factor Xa that escapes regulation is linearly dependent on the availability of TF.

[1]  Y. Nemerson,et al.  An ordered addition, essential activation model of the tissue factor pathway of coagulation: evidence for a conformational cage. , 1986, Biochemistry.

[2]  K. Mann,et al.  Extrinsic pathway proteolytic activity. , 1993, Methods in enzymology.

[3]  J. Miletich,et al.  The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action , 1988 .

[4]  G. David Solid state lactoperoxidase: a highly stable enzyme for simple, gentle iodination of proteins. , 1972, Biochemical and biophysical research communications.

[5]  D. Branam,et al.  Importance of Substrate Composition, pH and Other Variables on Tissue Factor Enhancement of Factor Vlla Activity , 1993, Thrombosis and Haemostasis.

[6]  S. Krishnaswamy,et al.  The activation of prothrombin by the prothrombinase complex. The contribution of the substrate-membrane interaction to catalysis. , 1994, The Journal of biological chemistry.

[7]  S. Rapaport,et al.  Isolation and characterization of human factor VII. Activation of factor VII by factor Xa. , 1981, The Journal of biological chemistry.

[8]  A. Guha,et al.  Tissue factor and its extracellular soluble domain: the relationship between intermolecular association with factor VIIa and enzymatic activity of the complex. , 1992, Biochemistry.

[9]  P. V. von Hippel,et al.  Calculation of protein extinction coefficients from amino acid sequence data. , 1989, Analytical biochemistry.

[10]  K. Fujikawa,et al.  The mechanism of activation of bovine factor X (Stuart factor) by intrinsic and extrinsic pathways. , 1974, Biochemistry.

[11]  J Jesty,et al.  Kinetics of the inhibition of factor Xa and the tissue factor-factor VIIa complex by the tissue factor pathway inhibitor in the presence and absence of heparin. , 1994, Biochemistry.

[12]  H. Hemker,et al.  Kinetics of the inhibition of human factor Xa by full-length and truncated recombinant tissue factor pathway inhibitor. , 1994, The Biochemical journal.

[13]  G. Broze,et al.  Tissue factor pathway inhibitor and the revised theory of coagulation. , 1995, Annual review of medicine.

[14]  G. Broze,et al.  Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. , 1993, The Journal of biological chemistry.

[15]  P. Neuenschwander,et al.  Factor VII autoactivation proceeds via interaction of distinct protease-cofactor and zymogen-cofactor complexes. Implications of a two-dimensional enzyme kinetic mechanism. , 1993, The Journal of biological chemistry.

[16]  W. Ruf,et al.  Identification of surface residues mediating tissue factor binding and catalytic function of the serine protease factor VIIa. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[17]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[18]  U. Pendurthi,et al.  Mechanism of antithrombin III inhibition of factor VIIa/tissue factor activity on cell surfaces. Comparison with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor VIIa/tissue factor activity. , 1995, Blood.

[19]  E. Davie,et al.  Activation of human factor X (Stuart factor) by a protease from Russell's viper venom. , 1977, Biochemistry.

[20]  Y. Nemerson,et al.  The tissue factor pathway of blood coagulation. , 1992, Progress in hemostasis and thrombosis.

[21]  J. Mason,et al.  HYDRODYNAMIC ANALYSIS OF EGG PHOSPHATIDYLCHOLINE VESICLES , 1978, Annals of the New York Academy of Sciences.

[22]  K. Mann,et al.  Activation of human prothrombin by human prothrombinase. Influence of factor Va on the reaction mechanism. , 1987, The Journal of biological chemistry.

[23]  D. Rader,et al.  Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. , 1991, Blood.

[24]  Y. Nemerson,et al.  Surface-mediated enzymatic reactions: simulations of tissue factor activation of factor X on a lipid surface. , 1995, Biophysical journal.

[25]  K Fujikawa,et al.  The coagulation cascade: initiation, maintenance, and regulation. , 1991, Biochemistry.

[26]  G. Nelsestuen,et al.  Interaction of prothrombin and blood-clotting factor X with membranes of varying composition. , 1977, Biochemistry.

[27]  G. Broze Binding of human factor VII and VIIa to monocytes. , 1982, The Journal of clinical investigation.

[28]  P. Coleman,et al.  Assay of coagulation proteases using peptide chromogenic and fluorogenic substrates. , 1981, Methods in enzymology.

[29]  Y. Nemerson,et al.  Factor VII binding to tissue factor in reconstituted phospholipid vesicles: induction of cooperativity by phosphatidylserine. , 1986, Biochemistry.

[30]  J. Morrison,et al.  Methotrexate, a high-affinity pseudosubstrate of dihydrofolate reductase. , 1979, Biochemistry.

[31]  P. Neuenschwander,et al.  Roles of the membrane-interactive regions of factor VIIa and tissue factor. The factor VIIa Gla domain is dispensable for binding to tissue factor but important for activation of factor X. , 1994, The Journal of biological chemistry.

[32]  K. Norris,et al.  Recombinant human extrinsic pathway inhibitor. Production, isolation, and characterization of its inhibitory activity on tissue factor-initiated coagulation reactions. , 1990, The Journal of biological chemistry.

[33]  S Krishnaswamy,et al.  The interaction of human factor VIIa with tissue factor. , 1992, The Journal of biological chemistry.

[34]  R J Baugh,et al.  Role of the Activation Peptide Domain in Human Factor X Activation by the Extrinsic Xase Complex* , 1996, The Journal of Biological Chemistry.

[35]  Susan G. Brown,et al.  Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor , 1989, Nature.

[36]  Kenneth G. Mann,et al.  Surface-dependent reactions of the vitamin K-dependent enzyme complexes , 1990 .

[37]  J. Miletich,et al.  Monoclonal anti-human factor VII antibodies. Detection in plasma of a second protein antigenically and genetically related to factor VII. , 1985, The Journal of clinical investigation.

[38]  G. Vlasuk,et al.  Assembly of the prothrombinase complex enhances the inhibition of bovine factor Xa by tick anticoagulant peptide. , 1994, Biochemistry.

[39]  V. Storme,et al.  High–Level Secretion and Very Efficient Isotopic Labeling of Tick Anticoagulant Peptide (TAP) Expressed in the Methylotrophic Yeast, Pichia pastoris , 1994, Bio/Technology.

[40]  J. Miletich,et al.  Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. , 1991, Blood.

[41]  G. Willems,et al.  Kinetics of the Inhibition of Tissue Factor-Factor Vila by Tissue Factor Pathway Inhibitor , 1995, Thrombosis and Haemostasis.

[42]  S. Rapaport,et al.  The Tissue Factor Pathway: How It Has Become a “Prima Ballerina” , 1995, Thrombosis and Haemostasis.

[43]  P. Kuzmič,et al.  Program DYNAFIT for the analysis of enzyme kinetic data: application to HIV proteinase. , 1996, Analytical biochemistry.

[44]  G. Broze,et al.  Tissue factor pathway inhibitor , 1997 .

[45]  N. Callander,et al.  Mechanisms of binding of recombinant extrinsic pathway inhibitor (rEPI) to cultured cell surfaces. Evidence that rEPI can bind to and inhibit factor VIIa-tissue factor complexes in the absence of factor Xa. , 1992, The Journal of biological chemistry.

[46]  K. Mann,et al.  Role of the membrane surface in the activation of human coagulation factor X. , 1992, The Journal of biological chemistry.

[47]  J. Shafer,et al.  Reaction pathway for inhibition of blood coagulation factor Xa by tick anticoagulant peptide. , 1992, Biochemistry.

[48]  E. Shaw,et al.  [2] Titration of trypsin, plasmin, and thrombin with p-nitrophenyl p′-guanidinobenzoate HCl☆ , 1970 .

[49]  H. Hess,et al.  Assay of inorganic and organic phosphorus in the 0.1-5 nanomole range. , 1975, Analytical biochemistry.